6533b7d2fe1ef96bd125ebd6
RESEARCH PRODUCT
Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approaches for These Tumors
Monica NotarbartoloNatale D'alessandroNicoletta VivonaManuela LabbozzettaPaola Pomasubject
Oncologymedicine.medical_specialtybiologybusiness.industryCyclin-dependent kinase 4Settore MED/06 - Oncologia MedicaInhibitor proteinBiochemistryEpigenetic therapy NF-κB inhibition Raf-1 kinase inhibitor protein triple-negative breast cancersInternal medicineRaf 1 kinaseGeneticsbiology.proteinCancer researchSettore BIO/14 - FarmacologiaMolecular MedicineMedicineIdentification (biology)businessTriple negativeEpigenetic therapyBiotechnologydescription
Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by poor prognosis because they are not amenable to targeted therapies. We have taken into account that altered expression of Raf-1 kinase inhibitor protein (RKIP), a tumor and metastasis suppressor and a promoter of drug-induced apoptosis, is frequent in TNBCs and may be involved in their aggressive biology. Interestingly, the analysis of the possible mechanisms of RKIP downregulation in TNBCs permits the identification and recapitulation of different possible approaches, including epigenetic modulation, e.g., by DNA demethylating agents or histone deacetylase inhibition, and NF-κB inhibition. These approaches are currently of great interest in the field of TNBC therapy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-01-01 |